Eli Lilly Sees 60% Q1 Growth as FDA Notes Foundayo Safety Issues
Eli Lilly reported 60% Q1 revenue growth driven by GLP-1 drugs Mounjaro and Zepbound with a consensus price target of $1,215 (26% upside) and 25 of 30 analysts rating it a buy. FDA’s database logged two serious Foundayo adverse-event reports—including liver-related complications—in 34 submissions since its April 9 launch.
1. Q1 Revenue Growth Fueled by GLP-1 Drugs
Eli Lilly delivered 60% year-over-year revenue growth in the first quarter, driven primarily by its GLP-1 portfolio. Mounjaro and Zepbound led sales gains as strong demand for obesity and diabetes treatments continues to accelerate.
2. Strong Analyst Consensus Points to 26% Upside
A consensus of 30 analysts assigns a $1,215 share price target, implying 26% upside from current levels. Twenty-five analysts rate the stock a buy, reflecting improved valuation metrics that align with Lilly’s robust fundamentals.
3. Early Safety Reports Raise Concerns Over Foundayo
Since its April 9 launch, Foundayo has generated 34 adverse-event reports in the FDA database, including two flagged as serious. One report involves a 56-year-old patient with liver complications and another cites edema and hypersensitivity in a 66-year-old, prompting expedited regulatory review.